Trevi Therapeutics’ (TRVI) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research note issued to investors on Wednesday,Benzinga reports. D. Boral Capital currently has a $19.00 target price on the stock.

A number of other brokerages also recently commented on TRVI. Leerink Partners increased their price objective on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Stifel Nicolaus boosted their target price on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Needham & Company LLC increased their target price on Trevi Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday, March 9th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $21.33.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $10.69 on Wednesday. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -33.41 and a beta of 0.94. The stock’s 50-day moving average is $11.15 and its two-hundred day moving average is $10.93. Trevi Therapeutics has a 1-year low of $4.85 and a 1-year high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.04. Equities research analysts anticipate that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rubric Capital Management LP lifted its position in Trevi Therapeutics by 88.0% in the second quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock valued at $46,669,000 after acquiring an additional 3,993,325 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Trevi Therapeutics by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 6,434,655 shares of the company’s stock worth $80,562,000 after purchasing an additional 607,669 shares during the last quarter. Viking Global Investors LP increased its position in shares of Trevi Therapeutics by 232.4% during the third quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock worth $46,929,000 after purchasing an additional 3,585,875 shares in the last quarter. Vivo Capital LLC increased its position in shares of Trevi Therapeutics by 13.5% during the third quarter. Vivo Capital LLC now owns 5,094,668 shares of the company’s stock worth $46,616,000 after purchasing an additional 606,765 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Trevi Therapeutics by 95.4% in the 3rd quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock valued at $44,302,000 after purchasing an additional 2,363,835 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Needham raised its price target from $22 to $24 and maintained a “buy” — a bullish signal implying substantial upside to current levels. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating with a $19 target, supporting demand from the buy-side. Read More.
• Positive Sentiment: Trevi achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and de‑risking milestone that materially increases the program’s commercial potential. Read More.
• Positive Sentiment: Q4 results showed EPS of ($0.06), beating consensus (−$0.10), and management provided business updates tied to the Phase 3 plan — supportive near-term fundamentals. Read More.
• Neutral Sentiment: Analyst/market write-ups are re‑examining TRVI valuation after the FDA alignment; these pieces can help inform longer‑term upside but don’t change near‑term cash/clinical timelines. Read More.
• Negative Sentiment: Morgan Stanley trimmed its price target from $19 to $18 while keeping an “overweight” rating — a modest downgrade to upside expectations that may have tempered buying enthusiasm. Read More.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.